Citations

Mayo Clinic

Showing 10 of 108572 citations.

Intradural Pituitary Hemitransposition: Technical Note and Case Series Illustration
Almeida, João Paulo , Finger, Guilherme , Weber, Matthieu D. , Wu, Kyle , Walz, Patrick C. , Leonard, Jeffrey R. , Carrau, Ricardo L. , Prevedello, Daniel M. , Wu, Kyle C , Carrau, Ricardo L , Prevedello, Daniel M , Almeida, Joao Paulo , Damante, Mark A.

Operative Neurosurgery | December 22, 2023 | Volume: 26 | Issue: 6 | Pages: 625-634

10.1227/ons.0000000000001036 | PMID 38132563 Get It

BACKGROUND AND OBJECTIVES: Lesions located in the retrosellar region, interpeduncular cistern, and petroclival region are among the most difficult to access in neurosurgery. Transcranial approaches are useful; however, the large distance between the surgeon and the lesion as well as the presence of major neurovascular structures surrounding the lesion may limit surgical exposure. A midline transsphenoidal route avoids transgression of the neurovascular plane and provides direct access to the interpeduncular cistern. To safely access the interpeduncular fossa, it requires mobilization of the pituitary gland. The pituitary hemitransposition technique permits mobilization of the gland, while preserving its venous drainage and arterial supply to the gland on one of its sides, preserving gland function. The authors aim to describe the intradural pituitary hemitransposition technique and to demonstrate its safe application for resection of skull base tumors in the retrosellar space. METHODS: The authors describe the surgical technique and illustrate its application in 5 cases of different types of skull base tumors, including a video demonstrating all the steps to perform this approach. In addition, the authors discuss the advantages and limitations of this technique compared with other approaches to the retrosellar space. RESULTS: The intradural pituitary hemitransposition technique was used to safely resect a chondrosarcoma, chordoma, craniopharyngioma, teratoma, and meningioma involving the parasellar and retrosellar spaces, while minimizing endocrine morbidity. We had one patient with mild, albeit permanent hyperprolactinemia and hypothyroidism after surgery. No other patients had permanent dysfunction related to surgery. CONCLUSION: The endonasal endoscopic intradural pituitary hemitransposition approach is an effective technique for resection of lesions located within the retrosellar and petroclival regions, allowing adequate exposure while potentially optimizing the preservation of the pituitary function.
Fertility concerns and treatment decision‐making among national sample of young women with breast cancer
Kermadec, Elisabeth de, Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Ligibel, Jennifer A. , Emmons, Karen M. , Partridge, Ann H. , Ruddy, Kathryn J , Partridge, Ann H , Zheng, Yue

Cancer Medicine | December 22, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/cam4.6838 | PMID 38131887 Get It

Abstract Background Diagnosis of breast cancer in young women has been shown to affect their decision‐making with regard to fertility and family planning. Limited data are available from populations across the U.S. regarding this issue; thus, we sought to describe fertility concerns and efforts to preserve fertility in a national clinical trial population of young breast cancer patients. Methods The young and strong study was a cluster‐randomized controlled trial testing an intervention program for young women with breast cancer. Patients were surveyed within 3 months after diagnosis and at 3, 6, and 12 months after. Surveys asked about sociodemographics, psychosocial domains, fertility concerns, and fertility preservation strategies. Univariable and multivariable models were used to investigate sociodemographic, clinical, and psychosocial predictors of fertility concerns. Results Of 467 women from 54 clinical sites across the U.S. (14 academic, 40 community), 419 were evaluable regarding fertility concerns. Median age was 40 years (range 22–45), 11% were Black, 6% Hispanic, and 75% had children. Tumor stage was I (35%), II (51%), or III (14%); 82% received chemotherapy. At time of the treatment decision, 133 (32%) participants had fertility concerns, among whom 47% indicated this affected their treatment decisions. Sixty percent of participants reported having discussed fertility with their physician. Twenty percent of those with fertility concerns used fertility preservation strategies. History of difficulty becoming pregnant and younger age were associated with higher odds of fertility concerns in multivariable modeling. Conclusion Many young women with newly diagnosed breast cancer are concerned about fertility in a way that impacts their treatment decisions. Concerns were discussed, but few used fertility preservation strategies. These findings have implications for counseling young patients.
Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
Anker, Christopher J. , Abood, Gerard, Hallemeier, Christopher L. , Kennedy, Timothy J., Kumar, Rachit , Lee, Percy , Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Jethwa, Krishan R. , Kim, Ed, Berlin, Jordan D. , Tchelebi, Leila T. , Hallemeier, Christopher Leigh , Jabbour, Salma K , Small, William , Russo, Suzanne

American Journal of Clinical Oncology | December 22, 2023 | Volume: 47 | Issue: 4 | Pages: 185-199

10.1097/coc.0000000000001076 | PMID 38131628 Get It

For patients with locoregionally confined pancreatic ductal adenocarcinoma (PDAC), margin-negative surgical resection is the only known curative treatment; however, the majority of patients are not operable candidates at initial diagnosis. Among patients with resectable disease who undergo surgery alone, the 5-year survival remains poor. Adjuvant therapies, including systemic therapy or chemoradiation, are utilized as they improve locoregional control and overall survival. There has been increasing interest in the use of neoadjuvant therapy to obtain early control of occult metastatic disease, allow local tumor response to facilitate margin-negative resection, and provide a test of time and biology to assist with the selection of candidates most likely to benefit from radical surgical resection. However, limited guidance exists regarding the relative effectiveness of treatment options. In this systematic review, the American Radium Society multidisciplinary gastrointestinal expert panel convened to develop Appropriate Use Criteria evaluating the evidence regarding neoadjuvant treatment for patients with PDAC, including surgery, systemic therapy, and radiotherapy, in terms of oncologic outcomes and quality of life. The evidence was assessed using the Population, Intervention, Comparator, Outcome, and Study (PICOS) design framework and “Preferred Reporting Items for Systematic Reviews and Meta-analyses” 2020 methodology. Eligible studies included phases 2 to 3 trials, meta-analyses, and retrospective analyses published between January 1, 2012 and December 30, 2022 in the Ovid Medline database. A summary of recommendations based on the available literature is outlined to guide practitioners in the management of patients with PDAC.
Sex differences in brain atrophy in dementia with Lewy bodies
Oltra, Javier , Habich, Annegret , Nedelská, Zuzana , Przybelski, Scott A. , Diaz‐Galvan, Patricia , Lowe, Val J. , Oppedal, Ketil , Philippi, Nathalie , Blanc, Frédéric , Barkhof, Frederik , Padovani, Alessandro , Massa, Federico , Kramberger, Milica G. , Snædal, Jón , Walker, Zuzana , Antonini, Angelo , Segura, Bàrbara , Westman, Eric , Kantarci, Kejal , Antonini, Angelo , Walker, Zuzana , Nedelska, Zuzana , Westman, Eric , Kantarci, Kejal , Barkhof, Frederik , Habich, Annegret , Diaz-Galvan, Patricia , Padovani, Alessandro , Massa, Federico , Segura, Barbara , Schwarz, Christopher G. , Inguanzo, Anna , González, Maria Camila , Lemstra, Afina W. , Hort, Jakub , Rektorová, Irena , Bonanni, Laura , Taylor, John‐Paul , Dierks, Thomas , Junqué, Carme , Boeve, Bradley F. , Aarsland, Dag , Ferreira, Daniel

Alzheimer's & Dementia | December 22, 2023 | Volume: 20 | Issue: 3 | Pages: 1815-1826

10.1002/alz.13571 | PMID 38131463 Get It

Abstract INTRODUCTION Sex influences neurodegeneration, but it has been poorly investigated in dementia with Lewy bodies (DLB). We investigated sex differences in brain atrophy in DLB using magnetic resonance imaging (MRI). METHODS We included 436 patients from the European‐DLB consortium and the Mayo Clinic. Sex differences and sex‐by‐age interactions were assessed through visual atrophy rating scales ( n = 327; 73 ± 8 years, 62% males) and automated estimations of regional gray matter volume and cortical thickness ( n = 165; 69 ± 9 years, 72% males). RESULTS We found a higher likelihood of frontal atrophy and smaller volumes in six cortical regions in males and thinner olfactory cortices in females. There were significant sex‐by‐age interactions in volume (six regions) and cortical thickness (seven regions) across the entire cortex. DISCUSSION We demonstrate that males have more widespread cortical atrophy at younger ages, but differences tend to disappear with increasing age, with males and females converging around the age of 75. Highlights Male DLB patients had higher odds for frontal atrophy on radiological visual rating scales. Male DLB patients displayed a widespread pattern of cortical gray matter alterations on automated methods. Sex differences in gray matter measures in DLB tended to disappear with increasing age.
Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
Gao, Lan , Kaushik, Diksha , Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Schwartz, Gary K. , Maliakal, Pius, Baird, John D. , Ma, Jiyuan , Barrett, Rosemary , D'Silva, Dhiren, O’Keefe, Kylie, Kong, Ronald , Van Tine, Brian A , Meyer, Christian , Schwartz, Gary K , Ingham, Matthew A

Clinical and Translational Science | December 22, 2023 | Volume: 17 | Issue: 2 | Pages: No page available

10.1111/cts.13709 | PMID 38129988 Get It

AbstractUnesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surrogate metabolite 5‐aminoimidazole‐4‐carboxamide (AIC) in 29 patients with advanced LMS. Drug interactions between DTIC (and AIC) and unesbulin were evaluated. DTIC (1000 mg/m2) was administered to patients with LMS via 1‐h intravenous (i.v.) infusion on day 1 of every 21‐day (q21d) cycle. Unesbulin dispersible tablets were administered orally twice weekly (b.i.w.), starting on day 2 of every cycle, except for cycle 2 (C2), where unesbulin was dosed either on day 1 together with DTIC or on day 2, 1 day after DTIC administration. The PK of DTIC, AIC, and unesbulin in cycle 1 (C1) and C2 were estimated using noncompartmental analysis. DTIC and AIC were measurable immediately after the start of infusion and reached maximum plasma concentration (Cmax) immediately or shortly after end of infusion at 1.0 and 1.4 h (time to Cmax), respectively. Co‐administration of unesbulin orally at 200 mg or above with DTIC inhibited cytochrome P450 (CYP)1A2‐mediated DTIC metabolism, resulting in 66.7% reduction of AIC exposures. Such inhibition could be mitigated when unesbulin was dosed the day following DTIC infusion. Repeated unesbulin dosing demonstrated evidence of clinical CYP1A2 induction and increased AIC Cmax by 69.4% and area under concentration‐time curve to infinity by 57.9%. No meaningful difference in unesbulin PK was observed between C2 and C1. The combination therapy of 1000 mg/m2 i.v. DTIC q21d and 300 mg unesbulin b.i.w. in a staggered regimen is well‐tolerated in patients with LMS.
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing
Turner, Amy , Haidar, Cyrine E. , Yang, Wenjian , Boone, Erin C. , Empey, Philip E. , Haddad, Andrew , Tahir, Saba, Scharer, Gunter , Broeckel, Ulrich , Turner, Amy J , Offer, Steven M. , Empey, Philip E , Haddad, Andrew , Scharer, Gunter , Gaedigk, Andrea , Yang, Wenjian , Gaedigk, Andrea

Clinical and Translational Science | December 22, 2023 | Volume: 17 | Issue: 1 | Pages: No page available

10.1111/cts.13699 | PMID 38129972 Get It

AbstractThe DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is the causal variant linked to the previously described HapB3 haplotype, c.1129‐5923C>G (rs75017182) in intron 10, which introduces a cryptic splice site. A benign synonymous variant in exon 11, c.1236G>A (rs56038477) is also linked to HapB3 and is commonly used for testing. Previously, these single‐nucleotide polymorphisms (SNPs) have been reported to be in perfect linkage disequilibrium (LD); therefore, c.1236G>A is often utilized as a proxy for the function‐altering intronic variant. Clinical genotyping of DPYD identified a patient who had c.1236G>A, but not c.1129‐5923C>G, suggesting that these two SNPs may not be in perfect LD, as previously assumed. Additional individuals with c.1236G>A, but not c.1129‐5923C>G, were identified in the Children's Mercy Data Warehouse and the All of Us Research Program version 7 cohort substantiating incomplete SNP linkage. Consequently, testing only c.1236G>A can generate false‐positive results in some cases and lead to suboptimal dosing that may negatively impact patient therapy and prospect of survival. Our data show that DPYD genotyping should include the functional variant c.1129‐5923C>G, and not the c.1236G>A proxy, to accurately predict DPD activity.
A Novel Acetone Sensor for Body Fluids
Pérez, Óscar Osorio , Nguyen, Ngan Anh, Hendricks, Asher, Victor, Shaun , Yu, Nanxi , Xian, Xiaojun , Kulick, Doina , Forzani, Erica , Xian, Xiaojun , Wang, Shaopeng , Perez, Oscar Osorio, Mora, Sabrina , Wang, Shaopeng

Biosensors | December 22, 2023 | Volume: 14 | Issue: 1 | Pages: 4

10.3390/bios14010004 | PMID 38248381 Get It

Ketones are well-known biomarkers of fat oxidation produced in the liver as a result of lipolysis. These biomarkers include acetoacetic acid and β-hydroxybutyric acid in the blood/urine and acetone in our breath and skin. Monitoring ketone production in the body is essential for people who use caloric intake deficit to reduce body weight or use ketogenic diets for wellness or therapeutic treatments. Current methods to monitor ketones include urine dipsticks, capillary blood monitors, and breath analyzers. However, these existing methods have certain disadvantages that preclude them from being used more widely. In this work, we introduce a novel acetone sensor device that can detect acetone levels in breath and overcome the drawbacks of existing sensing approaches. The critical element of the device is a robust sensor with the capability to measure acetone using a complementary metal oxide semiconductor (CMOS) chip and convenient data analysis from a red, green, and blue deconvolution imaging approach. The acetone sensor device demonstrated sensitivity of detection in the micromolar-concentration range, selectivity for detection of acetone in breath, and a lifetime stability of at least one month. The sensor device utility was probed with real tests on breath samples using an established blood ketone reference method.
Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients
Olteanu, Horatiu , Patnaik, Mrinal M. , Chen, Dong , He, Rong , Viswanatha, David S., Mangaonkar, Abhishek A. , Kourelis, Taxiarchis , Hines, Alexander , Reichard, Kaaren K. , Herrick, Jennifer L. , Chen, Dong , He, Rong , Viswanatha, David, Hines, Alexander S , Gibson, Sarah E , Koster, Matthew J. , Warrington, Kenneth J. , Go, Ronald S. , Gibson, Sarah E. , Peterson, Jess F.

American Journal of Clinical Pathology | December 22, 2023 | Volume: 161 | Issue: 6 | Pages: 609-624

10.1093/ajcp/aqad186 | PMID 38413044 Get It

Abstract Objectives VEXAS syndrome is an adult-onset autoinflammatory disease caused by a somatic pathogenic mutation in the UBA1 (ubiquitin-like modifier activating enzyme 1) gene. Patients present with rheumatologic manifestations and cytopenias and may have an increased predisposition to myelodysplastic syndrome (MDS) and plasma cell neoplasms. Prior studies have reported on the peripheral blood and bone marrow findings in patients with VEXAS syndrome. Due to the protean clinical presentation and lack of specificity of morphologic features (eg, vacuoles in early erythroid and granulocytic precursors), an optimal screening methodology to identify these patients in a timely fashion is desirable. Methods To further evaluate and describe the salient diagnostic morphologic features in VEXAS syndrome, we carried out a comprehensive study of the largest single-institution cohort to date. Diagnostic and follow-up bone marrow biopsy specimens from 52 male patients with molecularly identified VEXAS syndrome underwent central review. Results Cytopenias were common in all cases, primarily macrocytic anemia, monocytopenia, and thrombocytopenia. Bone marrow aspirate and biopsy were often hypercellular, with an increased myeloid/erythroid ratio, granulocytic hyperplasia with left shift, erythroid left shift, and megakaryocyte hyperplasia, which exhibited a range of striking morphologic findings. Distinctly vacuolated myeloid and erythroid precursors were seen in more than 95% of cases. Conclusions Our data reveal potential novel diagnostic features, such as a high incidence of monocytopenia and distinct patterns of atypical megakaryopoiesis, that appear different from dysmegakaryopoiesis typically associated with MDS. In our experience, those findings are suggestive of VEXAS, in the appropriate clinical context.
EXPLORING THE POTENTIAL OF PHLPP INHIBITORS FOR OSTEOARTHRITIS TREATMENT
Victoria-Sanchez, Leslie, Torres, Haydee, Westendorf, Jennifer J.

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 972-973

10.1093/geroni/igad104.3125 Get It

Abstract Osteoarthritis (OA) is a degenerative joint disease characterized by pain, stiffness, and limited joint motion affecting 7% of the world’s population. PH domain leucine-rich repeat protein phosphates (PHLPPs) have been identified as modifiable targets for cartilage regeneration and joint pain. PHLPP1 and PHLPP2 are abnormally expressed in osteoarthritic cartilage and sensory neurons. PHLPP1-/- mice are protected from cartilage degradation and pain-related behaviors (allodynia and reduced mobility) after surgery that destabilizes the medial meniscus (DMM). Here, we investigate the effects of PHLPP inhibitors (i) on human chondrocytes and the effect of Phlpp1 deletion on cell populations within lumbar dorsal root ganglia (DRGs). Immunohistochemistry was performed on mouse DRGs by cryosectioning fixed L3-5 DRGs and using primary antibodies against Fabp7, Anti tubulin beta 3, and PGP9.5/UCHL1. Human chondrocytes were subjected to Cycloheximide chase experiments and treated with PHLPPi (NSC117079 or NSC45586), followed by Western blot analysis to assess protein levels including Phlpp1, Phlpp2, Sox9, p-AKT (Ser473), total AKT, and B-actin, at various time points. We found that PHLPPi prolongs the phosphorylated AKT response when compared to controls and does not affect degradation of Phlpp1 or Phlpp2; additionally, NSC117079 increased production of cartilage extracellular matrix components (glycosaminoglycans and aggrecan) in over 90% of human articular cartilage explants from OA patients. These data advance our understanding of how PHLPPi function within chondrocytes and provide a basis toward understanding their activity and safety in vivo. Our results indicate that PHLPPi NSC117079 is a novel osteoarthritis disease-modifying drug candidate that may have palliative effects.
PRELIMINARY FEASIBILITY, UTILITY, AND ACCEPTABILITY OF THE TBI-AD/ADRD CAREGIVER SUPPORT INTERVENTION (TACSI)
Albers, Elizabeth , Louwagie, Katie , Finn, Jacob A. , Birkeland, Robyn , Ratner, Edward R. , Chesak, Sherry S. , Gaugler, Joseph E.

Innovation in Aging | December 22, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: 790-790

10.1093/geroni/igad104.2552 Get It

Abstract Research has established that dementia care partners may encounter socio-emotional and physical health concerns as a consequence of providing dementia care. Similarly, care partners for people living with Traumatic Brain Injury (TBI) often experience a range of stressors and negative mental health outcomes due to their care demands. This study aims to support the unique subset of family care partners facing the challenge of caring for relatives who have both diseases, Alzheimer’s Disease/Alzheimer’s Disease related dementia (AD/ADRD) and a history of TBI. Phase I of this study focused on the design and subsequent refinement of the TBI-AD/ADRD Caregiver Support Intervention (TACSI). TACSI is a six-session telehealth intervention providing tailored psychosocial and psychoeducational coaching. Session topics include education on TBI and dementia, stress management, lifestyle planning, and communication skills. In partnership with the Minneapolis VA and the Mayo Clinic-Rochester, we enrolled 15 care partners for Phase I. Mixed methods data from 3-month follow-up surveys and qualitative data from post-intervention interviews established the feasibility, utility, and acceptance of TACSI. Care partners found the program valuable and would recommend it to others. They reported that TACSI helped with their stress management. Some participants shared that TACSI would provide greater benefit to newer caregivers needing more education on the diseases and/or caregiving. Phase I feedback will be applied to improve TACSI content and delivery for the Phase II randomized controlled trial evaluation. TACSI Phase I utility, acceptance, and feasibility outcomes will be highlighted as well as next steps for evaluation.